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ABSTRACT
The incidence of asthma is on the increase and calls for research are growing, yet asthma is a disease
that scientists are still trying to come to grips with. Asthma research has relied heavily on animal use;
however, in light of increasingly robust in vitro and computational models and the need to more fully
incorporate the ‘Three Rs’ principles of Replacement, Reduction and Refinement, is it time to reassess
the asthma research paradigm? Progress in non-animal research techniques is reaching a level where
commitment and integration are necessary. Many scientists believe that progress in this field rests on
linking disciplines to make research directly translatable from the bench to the clinic; a ‘21st-century’
scientific approach to address age-old questions.
Introduction
Only two new classes of asthma drug have progressed from the laboratory to the clinic during the past 50
years despite considerable funding and effort [National Centre for the Replacement, Refinement and
Reduction of Animals in Research (NC3Rs); http://www.nc3rs.org.uk/news.asp?id51405]. In the
meantime, some 300 million people worldwide currently suffer from asthma and it remains the most
common chronic disease among children. Although most asthma-related deaths occur in low- and lowermiddle income countries, asthma is a public health problem globally. Approximately one in every 250
deaths worldwide is asthma related, and the incidence continues to increase (WHO;
http://www.who.int/mediacentre/factsheets/fs094/en/index.html).
During the past 10 years, the UK Medical Research Council (MRC) alone has provided £35 million in
funding for basic research on asthma (MRC, personal communication). However, a recent call from
NC3Rs for ‘new experimental models with improved scientific and clinical relevance and reduced reliance
on the use of animals’ sheds light on the obstacles facing asthma research in the UK (NC3Rs;
http://www.nc3rs.org.uk/page.asp?id51231). Recent European Union-funded projects under the Seventh
Framework Programme for Research and Technology Development (FP7) have also sought to explore
the asthma–environment link (Europa: Cordis; http://cordis.europa.eu). The Innovative Medicines Initiative
(IMI), a European project aimed at bringing medicines more quickly to the market, was launched in 2009
and has injected €246 million into research, including asthma. It is hoped that a large patient cohort will
enable validation of human biomarkers and development of diagnostic criteria for mechanistic and
therapeutic trials (Europa press release; http://europa.eu/rapid/pressReleasesAction.do?reference5IP/
09/802). The identification of this area as a bottleneck, along with the imbalance of progress and funding,
signifies the need to reassess the way that asthma research is carried out and to realign its direction.
Asthma is characterised by airway inflammation, airway hyper-responsiveness (AHR, which is defined by
exaggerated airflow obstruction in response to bronchoconstrictors), mucus overproduction, chronic

eosinophilic inflammation, airway remodelling and episodic airway obstruction [1]. The response of atopic
individuals is complex, involving an ordered interplay between mediators, cytokines and cell migrations
throughout the respiratory tract, draining lymph nodes and blood. It is now clear that a wide range of
environmental factors, superimposed on a genetic back-ground, determine the occurrence and severity of
asthma [2]. Although concerted international efforts of scientists and clinicians, the pathobiology of
asthma is still relatively poorly under-stood [3].
Epidemiological studies can yield a great deal of information and clinical investigations are powerful tools;
however, owing to ethical constraints and regulations surrounding clinical trials since the first mouse
models were published in 1994, there has been a general reliance on animal models for asthma studies
[3]. During this time, despite gleaning some information on the disease, progress has been slow in
elucidating information on the causes, onset, persistence and treatments, owing in part to limitations
associated with currently available models [3,4]. Despite asthma having originally been discovered as an
inflammatory disease through human studies [5], artificially induced animal models of the disease have
become increasingly prevalent, in particular murine models. Some investigators have described such
models as ‘indispensable’ from a drug-screening standpoint [6]; whereas others have observed that
animal models have intrinsic limitations [3].
The concept of ‘personalised medicine’ is especially relevant to a disease such as asthma, and the term
‘personalised research’ has been coined to demonstrate the need for basic research in asthma to reflect
the variety of phenotypes that patients present. In many cases, only a reductionist approach is possible;
however, complex behaviours of the larger system can be modelled computationally using systems
biology tools. With this in mind, there are techniques outside of the mainstream asthma research field that
have already shown great promise or that, with some targeted development, could be used to approach
the asthma questions from a different angle. In this review, I analyse the current models used in asthma
research and highlight the available components that could form part of a change in the way that asthma
research is conducted.
The current climate: animal models
The species of animal most commonly used in asthma research include dogs [3,6], sheep [7] and nonhuman primates (NHPs; principally rhesus and cynomolgus macaques) [8], as well as mice [9], rats [10],
cats [11] and guinea pigs [12], with the most prevalent being the murine model. Mouse models have seen
a dramatic rise in use over the past decade in an effort to probe the fundamental immunological causes of
the disease and to identify and test novel therapeutic strategies [13]. However, in earlier years, rats and
larger animal models were more common, having contributed to the identification of potential drug
targets: tryptase inhibitors [14], cysteinyl leukotriene receptor antagonists [15] antibodies against
interleukin (IL)-5 [16], and the understanding of certain allergic responses in the progression of the
disease [17]. However, as illustrated below, there is reason for caution in extrapolating the findings in
experimentally induced animal models to the naturally occurring human disease [18].
Modelling a human condition
Because most animals, with the exception of cats [19] and a very similar condition reported in horses [20],
do not spontaneously develop ‘asthma’ as it is characterised in humans [21], questions inevitably arise
when attempting to extrapolate research findings to humans. The pathophysiological differences between
humans and various animal species are significant when considering the relevance of experimental data.
There are several references detailing different methods for artificially inducing ‘asthmatic’ reactions in
various animal species, which are noteworthy owing to the effects that different methods can have on the

outcome of research. Among the most common general approaches for asthma induction is sensitising
the immune system to a previously unseen antigen and subsequently challenging the airway to the same
antigen, because following the cascade of events or a distant outcome that ensues some time after the
challenge [3]. A common challenge used with mice [22], rats [23] and guinea pigs [24] is the ‘ovalbumin
(OVA) protocol’, which involves intraperitoneal injection of OVA and an adjuvant (commonly aluminium
hydroxide) to prime the immune system [25]. This injection, which can be singular or with a booster
injection, is usually followed by an airway challenge of OVA. The resulting immunological response is one
similar to asthma and exhibits some of the inflammatory hallmarks. Criticisms of this technique include the
use of the adjuvant, which can alter the mechanisms of sensitisation that are being modelled and further
distance the animal model from the human condition [3]. In a bid to obviate the need for an adjuvant,
sensitisation methods have been developed that expose the immune system to an antigen together with
primed or altered T cells transferred to a naive recipient. Despite being more similar to the human
condition, the reaction of this model has been shown to be strain specific in mice, with varying results
[26]. Other recognised and more relevant human allergens have also been used in attempts to improve
the models, such as house dust mite [27] and cockroach antigens [28], Aspergillus fumigatus [29],
ragweed extracts [30] and adjuvants, such as proteases and cigarette smoke [31]. Sensitisation and
subsequent challenge with these approaches has resulted in clearly defined T helper 2 (Th2) type
responses in the lungs of mice with strain-specific responses, which has enabled genetic, cellular and
airway responses mechanism studies [32,33].
It has been suggested that the commonly used mouse models are of limited relevance to the study of
juvenile onset asthma [34]; the immune system physiology at birth is very different in mice and humans,
and development to an adult state occurs in a matter of weeks in mice versus years in humans [34,35].
The current view of asthma attributes the main effector role to T lymphocytes, specifically Th2 cells,
originally identified in mouse studies [17], but also obtained from studies demonstrating an increase in
Th2 cytokines in the lungs of patients [36,37]. Differences also exist within species; the most commonly
used mouse strains in experimentally induced models differ sharply in their propensity to cytokine
production in response to certain agents [35,38]. The BALB/c and C57BL/6 mice differ so much that the
choice of model profoundly affects the outcome of the experiment.
NHP models are favoured by some researchers owing to their ability to mount Th2 responses with
associated cytokine and chemokine production, alongside airway eosinophilia and increased levels of
immunoglobulin (Ig)E similar to that of patients with atopic asthma challenged with the appropriate
antigen [39,40]. However, NHP models do not demonstrate episodic wheezing, airway obstruction and
bronchoconstriction when exposed to atopic stimuli [41]. The influence of stress hormones on allergic
disorders and Th2 responses in NHPs have also been documented and should be taken into
consideration when reviewing studies involving monkeys [42]. The control over the sensitisation process
with NHPs is considered to be one advantage over other models, whereas the requirement for repeated
allergen challenge and time and labour constraints are drawbacks [35].
Airway remodeling
One of the key defining characteristics of asthma is the remodel-ling that occurs within the airways. This
process includes subepithelial fibrosis, goblet cell metaplasia and hyperplasia, mucus hypersecretion and
thickening of airway smooth muscle [43–47]. The remodelling is thought to be a result of the continued
expo-sure to allergen within the airway, which causes repeated inflammatory events [48]. Most mouse
models lack these chronic markers of asthma, because they are mostly based on the acute form of the
disease [41,49]. With mice, rats and guinea pigs, it has been shown that active sensitisation to an
allergen can result in a response but largely on the whole, a continued exposure of the antigen to the

airway will result in tolerance rather than chronic conditions [49,50] with the exception of some improved
studies that have demonstrated chronic remodelling features with repeated allergen exposure [51–53].
These also show promise in inducing a pathology that is similar to human asthma with long-term
sensitivity to bronchoconstricting agents.
Ultimately, if the intention of the model is to study and under-stand a chronic pathology, the acute method
is inadequate. One example of a different model that has been developed to display long-term AHR is the
dog model involving high IgE titre production on ragweed sensitisation [6]. The longevity has been
demonstrated for 5 months; however, the approach comes with other disadvantages, such as the labour
and costs associated with using dogs as models. Although dogs have a natural predisposition to develop
allergic responses to antigens with a clinical relevance to humans, they usually manifest such responses
with superficial reactions and the eosinophilia that develops in the airways in response to allergens does
not result in an increased responsive-ness for the airways. This is thought to be owing to the larger
anatomy of the dog airway [54]. The merits of using different animal models have been reviewed
elsewhere [41,55] and, in relation to airway structure, function and physiology, the differences between
the available models are substantial. Rat models represent an advantage over mice in being larger in size
and are therefore better suited to measure physiological outcomes, such as AHR. With the pronounced
IgE and inflammatory response post-sensitisation of the brown Norway rat, the mechanisms driving the
asthmatic phenotype can be studied [56]. Models of tolerance in rats enabled the discovery of T
regulatory cell importance in suppressing allergic responses [50]. Rats are a preferred model to mice
when considering the development of nonspecific AHR. The relative cost and lack of specific probes for
larger animal models of asthma has hindered their popularity in the asthma field [3]. Sheep, similar to
dogs, are known to mount allergic physiological reposes to certain inhaled allergens in a manner that
mirrors the patterns seen in humans: the response to challenge results in an influx of inflammatory cells
and mediators into the airway similar to the pattern of variation seen in patients with asthma [7]. Sheep
can also demonstrate nonspecific AHR together with similar responses to corticosteroids [7]. However,
many drugs that have shown effectiveness in sheep have shown poor efficacy in humans, especially
when working through platelet activation factor path-ways [55]. The response to allergen challenge in
NHPs closely resembles that of humans in terms of physiology and immunology, and can develop chronic
asthmatic phenotypes, such as extensive airway remodelling [57].
Age, genes and environment
The influence of genetic factors in asthma progression is exemplified with certain individuals being
predisposed to a certain phenotype [58]. These genetic factors, combined with environ-mental influences,
will determine whether an individual will go on to develop clinical asthma, with the exception of the few
late- or adult-onset cases [59,60]. Such events include: viral infection [61], exposure to allergens [62] and
other environmental factors, such as pollution and smoking [60], pets [63], bacterial by-products [64] in
the in utero environment. The latter illustrates one of the primary limitations of most current animal
models: the predominant use of adult animals. It is possible to predispose an animal genetically to
develop asthma-like reactions or sensitivity to a specific allergen, and different strains of mice can be
used to study heritability of traits typical of patients with asthma, but these are all mechanistically specific
and do not enable the multifaceted development of the disease as it presents itself in humans. The
substantive immunological differences between juveniles and adults [65], such as signalling deficiencies
in infant T cells, and the process of immunological education with age are often neglected with animal
models with only a few neonatal murine studies existing in the literature [66]. The mechanistic limitation of
the guinea pig as a model especially for genetic studies is a major drawback of this model. However,
there is more agreement between pharmacological responses of guinea pig and human airways than
those seen in rodents [41]. There are relatively few studies using NHPs at a young age [40].

The key players
In addition to the documented immunological differences between mice and humans [67], the cell-specific
reactions related to asthma are fundamental to the human form of the disease. Plasma exudation is a key
sign of bronchial asthma; the several plasma-derived, inflammatory, repair, leukocyte and growth factor
active proteins distribute readily in the human airway [4]. This is not seen in the mouse, even with a heavy
allergen overload [34]. The inflammatory cell types also differ: eosinophils in mice accu-mulate readily, yet
this distribution is considerably different from humans and, more significantly, the murine eosinophils do
not degranulate [68]. Exudation and eosinophil degranulation correlate with disease severity. In addition,
rodent mast cells release serotonin, which is not thought to have a role in human asthma [21]. Responses
related to target cell secretion of cytokines also differ between mice and humans; IL-3 elicits a stronger
response to murine structural cells than to those observed in human airway cells [69]. Likewise,
differences between the production and regulation of transforming growth factor (TGF)-b exist between
species [70,71]. Information is limiting regarding growth factor release and expression in both human
asthma and mouse models. However, after a periodic 2-year allergen challenge study in macaques,
changes in IgE, airway physiology and eosinophilia consistent with chronic asthma were observed. In
particular, IL4, IL5 and IL13 were expressed and corticosteroid treatment was found to be effective on
serum histamine levels [57].
Studies involving transgenic mice have underscored the importance of IL-4 [72], IL-5 [73] and IL-13 [74],
thought to be key mediators in the Th2-driven allergic response in a large proportion of patients with
asthma [18,41]. From such studies, several potential therapeutic targets were identified, although in
human clinical trials, the efficacy seen in mouse models of asthma could not be replicated [18]. Although
mice have been useful for mechanistic studies looking at switching off, suppressing or upregulating single
molecular pathways [72,75], transgenic mouse studies are only able to illustrate the importance of a
particular mediator or path-way in that particular animal using a specific protocol. When expanding many
studies to larger interventions, such as knockout molecules and increasing the range of animal models, it
is often the case that the results are not transferrable to the human condition, as is the case with Very
Late Antigen-4 (VLA-4), bradykinin, IL-4, and neurokinin studies [76–78]. In total, three studies involving
mice have identified airway response targets, have translated to human clinical benefits, for each of these
targets substantive human evidence was also available [79].
A further consideration regarding the transgenic animal paradigm is that the pathology of some of the
spontaneously developing airway remodelling is more akin to that of chronic lung disease than asthma.
Although many of these models enable the consequences of high levels of a particular mediator to be
observed, they could in fact be overemphasising the contribution of that particular molecule [80].
Considering anatomy and function
In addition to interspecies differences at the cellular level, there are also several anatomical differences to
consider. The major clinical symptom of asthma in humans is difficulty breathing; this is also the leading
cause of morbidity in patients [3]. Breathing difficulties result from restricted air flow, which can occur
through airway blockage, constriction or collapse, which could be caused by the thickening of the walls,
smooth muscle contraction, inflammatory exudates, and/or alterations in the parenchymal–airway
interaction [81,82]. When designing a disease model, these factors should be taken into account, given
that the ultimate aim is to mimic human clinical pathology to elucidate the underlying mechanisms. These
features have been seen in a selection of cases. Sheep, for example, exhibit bronchoconstriction of the
airways both immediately after allergen challenge and nonspecific AHR [83]. Similarly, some mouse [84]
and NHP studies show bronchoconstriction [85], whereas cats have also shown airway collapse and

excessive mucus accumulation [86]. Mice studies have demonstrated smooth muscle mass build up and
remodelling in extra bronchial lung vasculature [87], as well as airflow limitation [88]. However, many
models also display characteristics that are not present in patients with asthma, such as the lung
parenchymal and vascular inflammation and subepithelial deposition of matrix proteins, as seen in mice
[3]. Dogs do not demonstrate the asthma-like reactions in the airway, largely attributed to their unique
airway anatomy [41].
A significant number of the animals used as models are quadrupeds, which has bearing on the forces
acting upon the lungs, owing to gravity and the chest wall [89,90]. Airway branching pattern and
morphology also vary among species, which can affect aerosol deposition [91]. For example, an inverse
relationship exists between body size and relative airway calibre among rodent species, and mice in
particular have a limited proportion of smooth muscle in their airways. Inhalation studies relying on the
obligate nasal nature of murine inhalation are already disadvantageous owing to this fundamental
difference [91].
The frequency of cell types and receptor classes along the air-ways also differ within and among species
and strains [92]. There is no bronchial circulation in mice, which is likely to have an effect on cell
migration [93]. The increased ease with which allergic responses can be measured and the similarity in
size to the human structure, morphology and function of the airway means that larger animal models
perform better than murine models in this regard. The comparative anatomy of small and large animals
has been extensively reviewed and highlights that larger animals are more useful to mimic key anatomical
and physiological para-meters, such as blood vessel alternations [55,93]. Research techniques will also
have a bearing on the results owing to stress caused to animals during experimentation, which can in turn
affect physiology and behaviour [94].
With regard to lung function, the varying sizes of the different animal species used in comparison to one
another and to humans become an issue [3,55,95]. Measuring this parameter in the smaller animal
models is technically challenging [95,96]. It has become apparent that the most precise techniques are
the most invasive, and also represent those furthest removed from natural breathing conditions [96]. By
contrast, the technique that monitors breathing in the most natural circumstances bears a significant
sacrifice in terms of precision [3]. An example of one of the less invasive technique is noninvasive
barometric plethysmography measuring Penh (enhanced pause), which to its disadvantage is highly
dependent on breathing frequency. Mice are obligate nose breathers, so the method is affected by upper
airway inflammation. Such issues have led to widespread criticism of the method [97]. By contrast,
invasive techniques that require anaesthesia, tracheotomy or intubation and mechanical ventilation
require care and attention when extrapolating results to humans, and the limitations of these approaches
must be recognised [34]. Anaesthesia has been shown to affect asthma mouse models acting at the
airway level, lung periphery and also lung pressure readouts [98]. Large animals, such as sheep, dogs,
pigs and NHPs have a respiratory capacity similar to small adult humans [3]. When looking at lung
function, para-meters such as lung airflow and breathing rates are comparable between humans and
sheep, such that procedures that do not require patient cooperation are often carried out on sheep to
investigate pulmonary functions in addition to the peripheral airways and bronchial circulation [99]. Airway
biopsies and continued lung function testing are possible in large animals and deteriorating lung function
can also be analysed for several months [100,101]. The wedged bronchoscope technique and forced
oscillation technique can be used in dogs and sheep to measure collateral system resistance [101,102]
owing to the extensive collateral network of these species, which is absent in mice, pigs and horses [55];
a single animal can also be subjected to different treatments owing to the specificity of the technique,
which many scientists prefer because it serves as a refinement method [41].

The genetic and physiological similarities shared between NHPs and humans, especially the similarities
during postnatal development along with lung function and anatomy likeness, make it easy to carry out
pulmonary function measurements with techniques and instruments similar to those used on humans but
not requiring consent [40]. Noninvasive forced oscillation is commonly used and provides similar results
to those in humans, which is considered more relevant because it does not require anaesthesia [103].
However, the impact of stress on the animal when using this technique has not yet been studied.
Rodent use has dominated in asthma research owing in large part to their small size, low cost, short
lifespan and copious pre-existing published data. The relatively higher purchase and maintenance costs
together with a less developed understanding of disease mechanisms are issues to consider in regard to
large animal models [55,93]. In addition to the legal requirement in Europe outlined in Directive
2010/63/EU [104] and public policy drivers elsewhere, which integrate the principles of the 3Rs [105],
there are compelling reasons for refocusing research efforts. Fundamental tenets of Directive 2010/63/EU
are that experiments should not be performed if another scientifically satisfactory non-animal method of
obtaining the result sought is reasonably and practicably available and that a mandatory contribution to
the development of alternative approaches in research, as well as in testing, is required. Given that: (i)
animal models do not reproduce all of the main phenotypes of the disease as seen in humans; (ii) the
process of interspecies extrapolation is dubious at best and there is urgent need for better translation
between the bench and the clinic; and (iii) there are strong ethical and economic drivers pointing to the
need for applying the 3Rs in research, it seems prudent to explore the applicability of various non-animal
tools and technologies to the asthma research paradigm.
Modelling without animals
In vitro studies are often cited as lacking the biological complexity of an in vivo system; yet it can also be
said that animal models are a ‘black box’ of sorts that also do not permit a complete understanding of the
complex mechanistic interactions within an animal, or the differences between humans and a model
species. According to some researchers, the complex mechanisms underlying the genetics of
sensitisation and pathophysiology necessitate in vivo studies. They regard the mouse model as a
thorough means of replicating the clinical course of disease and long-term effects in the laboratory and
contend that in vitro models might not truly reflect the in vivo conditions with systemic mechanisms
contributing to responses in the disease state. The lack of models spontaneously developing asthma led
researchers to create knockout mice [106] and human–mouse chimeric models [107]; yet there is still
much uncertainty surrounding the behaviour of human cells within the mouse infrastructure, and whether
allergic or nonallergic asthma is being mimicked. Models produced using different experimental strategies
have generated conflicting results, although the reason for the divergence is sometimes unknown, which
underscores the need to treat results with caution [104,108]. A comparison summary of in vivo and in vitro
methods is given in Table 1.
In light of the slow progress achieved using in vivo approaches thus far, the inherent uncertainties of the
animal models and the potential benefits of advanced non-animal approaches, such as human patient
studies, 3D cell culture systems, computer model-ling and mechanically engineered models [105], one
must question whether continued reliance on the animal model is simply a case of remodelling an
inadequate model.
Some of the major questions facing asthma researchers today include: how is airway remodelling
initiated? Is it related to inflammation or does it represent a separate genetic determinant of asthma? Is
airway remodelling reversible? Is it therefore a potential therapeutic target [109]? In the current research
climate, each of these questions can be explored in part through in vitro techniques.

TABLE 1
A summary of asthma research methods

Methods

Examples

Features

Limitations

Refs

In vivo
models

Mouse
Dog
Sheep
NHP

Complex systems
Multiple variable can be evaluated

Not exact replicas of human disease

[6-103]

Many different models
Small animal models have short lifespan
so disease progression can be studied

Lack genetic heterogeneity
Use of different techniques to
generate transgenesis can lead to
different results
Larger animal model are expensive,
less available and have longer
lifespans
Ethical consideration regarding the
use of animals in science
Long-term effects cannot be
observed
Interactions with microenvironment
not observed

In vitro
cultures

Calu-3
NHBE
BEAS-2B
16HBE14-o

MatTek Epiarway™
Epithelix
MucilAir™

Human
tissue and
organ
explants

In silico
modelling

Computer modelling

Compugen Simpheny

Larger animal models share more
similarities with human physiology and lung
anatomy
Transgenic animals offer means of
evaluating genetic effects
Long lifespan
Not transformed
Differentiated
Can form cilia
Some secrete mucus
Cytokine secretion
Can express antioxidants
Tight junction formation and multi-layered
Easy access to cells
Primary cells, not transformed (bronchial,
nasal and tracheal origin)
Long life-span (1 month to 1 year),
differentiated and multi-played
Can form cilia, secrete mucus and forms
tight junctions
Structure and microenvironment
maintained
Cell interactions can be visualized and
cytokine production, chemokines and
inflammatory effects observed
Can be used in conjunction with other
techniques, such as videomicroscopy
Models of human airways and vascular
branching, bronchoconstriction,
inflammation, physiology, interactions
between immune system and allergens
and metabolic pathways

Genomatica Accelerys

Virtual patients
(Physiome and
Physiolab)

Genetic
studies

Molecular phenotyping
Linkage analysis
Genetic mapping
Epigenetic studies
Microarray analysis

Exploiting
available
data

Patient data
Medical records

Complex disease modelling is possible
Can reflect disease heterogeneity and
severity of disease
Fast and high-throughput methods
Hypothesis-driven research
Incorporates a variety of scientific fields
Provides useful direction for further
research
Can examine and identify candidate genes
Possibility to study interaction of
environment and genetics with epigenetic
studies
Integration with systems biology provides
useful way to identify candidate genes and
microarrays can highlight potential markers
Wealth of patient data available
Models of acute changes can be studied
over years
Medical records can be used to watch
trends

[110-129]

Cells not immortal
Cost to purchase

Differences in pathophysiology
between patients
Short lifespan of tissues
Limited accessibility
Ethical considerations
Difficult to study disease
development
Still relatively undeveloped, will
require large amounts of further
work
Requires wealth of data and
coordination of data sharing
Models require validation, (models
work on what is known, if the
mechanism is not clear then the
model might display errors)
Unknown challenges ahead

Often difficult to interpret, to work
with and uncover Complex field

[130-135]

[136-150]

[151-162]

Undeveloped area for asthma
research
Used as a highlighting tool so far

Requires effort to integrate and
connect the networks of data
Requires patient collaboration

[163-168]

In vitro cultures
Owing to the inaccessibility of the bronchial system, human studies have historically been limited to
bronchial biopsies and whole-lung tissue studies. However, with advances in cell culture techniques,
opportunities to develop in vitro models relevant to asthma have emerged. In vitro models can use cells
or respiratory tissue explants; the ease with which human cells can be accessed, isolated and purified
from peripheral and cord blood and respiratory tissues or obtained from sputum, nasal or bronchial
washings and biopsies, means that they can be cultured and analysed for phenotypic or genetic features.
Lavage studies can generate human samples for ex vivo analysis and, more recently, radiologically
guided bronchial brushings in patients with lung transplants have been performed to obtain small airway
epithelial cells for the establishment of submerged cell cultures with direct translatability to asthma studies
[110]. Evidence from in vitro cell culture work has suggested that the bronchial epithelium is fundamental
to the development of allergic pathology and that the relationship between the bronchial epithelium, stem
cells and the mesenchyme is crucial [111,112]. Therefore, mixed cultures of bronchial cells have great
potential for testing therapeutic targets; indeed, one culture system of bronchial biopsy explants was
developed successfully to gain insight into which cytokines are involved with perpetuating allergeninduced inflammatory processes in the asthmatic airway [113,114].
Through the use of immune cells from healthy subjects and patients with asthma, both the adaptive [51–
54] and innate [115,116] immune responses can be analysed. Individual cell types, such as Th2 cells
from blood and the respiratory tract, blood-derived eosinophils and antigen-presenting cells (APC) from
peripheral blood mononuclear cells (PBMC), have been isolated to reveal properties specific to the
allergic response of asthma (e.g. the discovery that specific allergens bring about degranulation and
elastase release in neutrophils [117]). Using bone marrow-derived stem cells, which can differentiate into
eosinophils, from patients with asthma and their offspring, might also shed light on the development of
allergic disease [118]. The in vitro use of innate immune cells has been cited as a promising approach for
elucidating disease pathogenesis and target identification [119]. The immunological nature of asthma
necessitates a human-specific approach when designing experiments; therefore, the most reliable cell
sources would be human derived, especially considering the immunological variations between species
[67]. It has been speculated that new models of allergic asthma could evolve from in vitro research with
differentiated stem cells provided by individuals [119].
The choice in in vitro studies between the use of primary cells and immortalised cell lines is an important
one [120]. Although cell lines offer the advantage of a limitless supply of experimental substrate, which in
some instances is amenable to chronic studies, concerns regarding the biological relevance of
immortalised (usually cancer) cell lines and their potentially high variability are substantial. By contrast,
primary cells offer clear advantages in terms of relevance to normal human biological activity, but also
have their limitations, including donor variability and functions, such as cytokine secretion, being crucially
dependent on the culture technique used [121]. However, human-derived primary cells appear to be the
most appropriate for biologically relevant modelling of human disease. Early technological limits to the
use of primary cells have been eased since advances in tissue engineering and the manufacture of
biological scaffolds, so much so that BéruBé and colleagues used tissue-engineered primary cells as in
vitro trachea–bronchial constructs for inhalation toxicology, predicting the efficacy and toxicity of drugs
[122]. The study of human bronchial epithelium was made possible by the production of human
bioengineered bronchial tissue equivalents [114]. Bronchial epithelial cells and fibroblasts taken from
biopsies from healthy subjects and patients with asthma can be cultured on a mesenchymal layer and will
undergo differentiation into ciliated goblet cells in a stratified epithelium mimicking the human bronchi.
This model can offer insights into physiological and pathophysiological responses of the bronchial
epithelium and the intricate interactions between the allergic response of asthma and the respiratory tract.

Often seen as a viable alternative to animal experimentation, cell and tissue culture systems are
indispensable in biomedical research. Tissue engineering, however, offers a functional approach to
disease research, whereby organised frameworks of cell types provide a network of interactions
exhibiting original characteristics occurring on a small or large scale. At a 3D level, the interplay among
cell signals, soluble factors and physical forces within a cellular environment can be captured. The
standardisation of such environments can be difficult and prior knowledge of the immune response and
cellular interplay is required to create effective experiments [3]. There are now several in vitro models
available, most of which focus on the bronchial epithelium owing to the numerous pathologies associated
with this region. These models exhibit complex characteristics afforded by advances, such as synthetic
biomatrix development, bioreactors for culture inserts and quantitative cell viability tests. Primary cells for
these cultures can be obtained from several sources: patient donations after surgery or postmortem
tissues [normal human bronchial epithelium (NHBE), Mattek EpiAirwayTM or Epithelix MucilAirTM], cells
generated from cancerous tissues (calu-3), and primary cells trans-formed by viruses (BEAS-2B or
16HBE14o-) [123].
The most commonly used stand-alone model is NHBE tissue grown in an air–liquid interface (ALI). For
example, the MucilAirTM construct incorporates basal, goblet and active ciliated cells, mucus, active ion
transport, metabolic activity and a range of chemokines and cytokines, functional for more than a year.
The increased availability of oxygen at the ALI surface, compared with that of the submerged culture,
causes epithelial cells to exhibit an increase in ciliation, recapitulating the in vivo-like surface phenotype.
This makes ALI cultured models useful for deposition experiments on the lung surface, which can then be
further examined using proteomic, morphological analysis and toxicogenomic tech-niques [124]. The
longevity of NHBE cells enables acute, chronic and repeat studies to be carried out. It is now also
possible for researchers to create an in-house human tissue-equivalent using medical waste from human
tissue banks or companies and expanding them for their own use. Advantages of these systems include
low maintenance costs, ease of handling and of deriving materials for analysis. MucilAir is not only
morphologically and function-ally differentiated, but it can also be maintained in a homeostatic state for
more than a year [125]. This makes it possible to study the initial and chronic aspects of asthma disease
and the interaction between different cell types, the elucidation of genetic determinants of the disease and
drug-screening possibilities.
3D cell culture constructs have developed rapidly over the past few years into accurate and advanced
models of disease states and present interesting possibilities if developed further to enable them to mimic
a broader association of the key players in asthma. A 3D tissue construct using three distinct primary
human cell types, human umbilical vein endothelial cells (HUVECs), normal human bronchial epithelial
cells and fibroblasts (NHBE/Fs), was cultivated on a fibrin gel with soluble mediators and an ALI for the
NHBE cells, and was successfully characterised and validated as a model of human airway mucosa. The
model was used to examine cell–cell synergistic interactions [126]. Similarly, Tomei and col-leagues
developed a 3D model that, at 21 days, exhibited a pseudostratified epithelium comprising basal cells,
mucus-secreting cells and ciliated columnar cells with beating cilia. Using micro-particle tracking, the
investigators were able to observe transport between groups of cells and, coupled with immunostaining,
tight junction loss after mechanical stress was observed. The model was well defined, reproducible and
controllable, making this a powerful tool for asthma research [127].
The development of advanced in vitro systems and their integration with other methodologies maximises
the usability of resulting models and the information that can be obtained. Researchers incorporated
atomic force microscopy in a study looking at spreading and migration of cells to determine the effect of
corticosteroids on epithelial cell wound repair [128]. Similarly, Persoz and colleagues designed and
adapted an in vitro model using a direct exposure device for studying lung epithelial cells to under-stand

the effects of air pollutants suspected of exacerbating asthma. Their model demonstrated the feasibility
and sensitivity of the exposure system for testing inflammatory cellular effects of gases at environmental
doses directly on human respiratory cells [129]. Extending the integration of methodologies beyond
disciplines and incorporating the skills and techniques of other scientific fields will not only offer the
means to answer outstanding questions, but potentially offer scope for connecting asthma research
angles, thus creating a more innovative research field. Currently, cellular in vitro assays do not model the
complexity of the disease sufficiently in contrast to tissue explant models (Table 1).
Human tissue and organ explants
Despite the fragility of the lung, it is possible to culture human organ explants under perfusion conditions.
Using human tissue explants as models of allergic asthma offers a clear advantage over cell cultures in
that the structure and the microenvironment within the tissue is maintained. Therefore, it is possible to
monitor the interactions of the cells with this environment, and measurements of mucus production and
bronchial constriction can be made, together with an assessment of cell functions through bronchial cell
chemokine [130] and cytokine production, and inflammatory effects on epithelium [131].
Results obtained from donor models of this kind have been disparate between different patients,
indicating the differences in pathophysiology and the importance of determining the predictivity of the
model. Taking the use of explants a stage further, precision-cut lung slices maintained in patient serum
are also a valuable tool when coupled with video microscopy to record the bronchoconstriction process
[132]. Khan and colleagues used lung explants to investigate the effects of enzymatic digestion on the
rate of airway narrowing. Corroboration of their results was performed using a computational model [133].
Additionally, bronchial rings have been maintained after surgical procedures to explore allergen challenge
[134]. The availability of intact tissues from the relevant species is desirable from the standpoint of
biological relevance; however, it is recognised that the limited accessibility and short lifetime of human
primary tissue samples impose major limitations on this avenue of research. Only a limited number of
approaches are currently ethically acceptable and humans usually have the disease before they are
studied, which renders dynamic studies of asthma development and dis-ease control difficult, but not
impossible if one considers occupational asthma [13]. Lung tissue models require bronchial biopsy, which
although safe, is not a trivial process [135]. However, the lack of availability and practicality issues
surrounding the use of human tissues would benefit from the expansion of human organ and tissue banks
and would be a direct benefit to research [132].
In silico modelling: virtual patients
The advent of in silico technologies has yet to penetrate the asthma research field fully; nevertheless, it
represents the newest wave of modelling technology in asthma research. Computer models of human
airways and vascular branching can take into account spatial arrangements of the airways, allowing for
the study of bronchoconstriction [136], inflammation of the airway wall, inter-actions between
aeroallergens and the immune system [137], the links between airway narrowing and the functional
effects of airway remodelling [138], thickening of the mucus layer and effects of disease on deposition of
inhaled particles [139]. This methodology is simple and accurate to use and is more relevant than any
animal species in reproducing human lung airway behaviour, as illustrated through experimental
validation [140]. The comparability of human lungs to anatomically accurate computer models was
demonstrated when a wedged bronchoscope using human subject data was found to be similar, thereby
corroborating the use of this model. When it comes to the deeper mechanisms of the lungs, for example
cellular behaviour and the intricate path-ways, it will be interesting to see how computational models can
contribute. Some systems, such as SimPheny, have been developed with this purpose in mind

(GT
Life
Sciences;
http://www.gtlifesciences.com/technology/Simpheny.html).
Genoma-tica
(http://www.genomatica.com) examines aspects of physiology and Compugen (http://www.cgen.com)
models are able to predict protein–protein interactions based on experimental and clinical data. There are
now projects focusing on the data collation and building the bioinformatics databases needed to make the
models, such as Accelerys (http://www.accelrys.com). Mathematical descriptions of the changes in
human lungs produced by asthma have been developed and reflect the heterogeneity and severity of the
disease. Mathematical modelling using basic fluid dynamics to characterise airway resistance has been
applied to examine the effects of airway smooth muscle shortening and thickening on changes in
pulmonary resistance. Use of this technique has shown that muscle mass is the most probable
abnormality responsible for increased resistance observed in asthma [141]. Similarly, airway narrowing
[142] and mucosa integrity predictions have been made using other models [143].
In drug discovery, in silico screening for the identification of novel therapeutics is useful and is commonly
where in silico methods tend to be placed. However, there is promise for many in silico techniques to also
be exploited at the bench level, which would provide a direct transition to the clinic and drug trials,
sidestepping the early involvement of animal models. The PRE-DICT model and algorithm were used as
an in silico technique in drug discovery for G protein-coupled receptors (GCPRs), an important family of
drug targets, without the requirement for structural information on receptors [144]. This type of highthroughput screening approach, although discussed in terms of drug discovery, is also a potential
technique in basic research, given that the protein structure and the membrane environment are the only
requirements for finding potential chemical binding partners, which can be human specific.
Perhaps the most promising of the in silico technologies is the ‘virtual patient’. Initiated to reduce costs in
bringing drugs to market, the virtual patient is also a suitable model to study pathophysiology mapped to
patient data because simultaneously reflecting the patient variability. It therefore provides a major impetus
for further development. Computer simulations have led to the generation of the ‘virtual lung’, a 3D model
of a human respiratory tract that provides a physiologically relevant set of measurements of healthy and
asthmatic lungs. Models can be built from several technologies, the most recent being single photon
emission computed tomography (SPECT), high-resolution computed tomography (HRCT) and magnetic
resonance imaging (MRI), with the latter being able to resolve the geometry of very small airways [145].
Virtual organs enable researchers to evaluate bronchoconstriction, inflammation and mucosal thickness,
and have been used to predict the efficiency of aerosol drug delivery [146]. The role for these models in
studying aerosol therapies is apparent from their proven ability to model particle transport, flow and
deposition. Their continued application will facilitate the study of the fate of inhaled particles of a range of
sizes and in different respiratory conditions for each individual specification [147], which has obvious
advantages at the bench. Additionally, the morphological model could facilitate the development of
methods for validating computational fluid dynamics studies with SPECT data. The virtual modelling
procedure is fast, low cost (many of the software programs are free), and human and patient specific. The
models depend on accurate MR/SPECT/HRCT images, which are readily available.
The ‘Physiome’ project (http://www.physiome.com) embodies the concept of integrative biology; it
provides a quantitative and integrated description of the physiological state of an individual or species in
terms of function, which is built on information (genomic, proteomic and morphometric) and structure. At
the smallest level, it incorporates details on cell biochemistry, endocrinology and systems up to organs,
and looks at genome and gene regulation in connection with the functional behaviour of the organism.
There are several models from which to choose, including lungs, which promote the use of
comprehensive data-bases of information already available and an integrative and analytical approach to
studying disease. It is essential to make use of all relevant and reliable existing data, which will provide a
useful basis for comparison to the human system and aid in minimising de novo animal use. A model can

only be as accurate as the data upon which it is based, so pools of robust data must be available.
Researchers working on the Physiome project state that this is only the very beginning, and many
challenges lie ahead, such as linking the models to clinical data and to the standard image formats widely
used in clinical imaging devices, such as MRI, and applying the physiome to genotype–phenotype
questions [148].
Using the 3D arbitrary Lagrangian–Eulerian (ALE)-based fluid-structure interaction (FSI) method,
researchers investigated respiratory flow in a human virtual airway bifurcation with rigid and compliant
walls. This airway model is a realistic model based on multi-detector computed tomography (MDCT) data
demonstrating the importance of airway wall motion in influencing airway flow patterns [149]. US-based
Entelos Inc. (http://www.entelos.com/index.php) is developing mechanistic mathematical models of
human disease, including asthma, using their patented PhysioLab1 technology. The models can be used
in early target information studies through to Phase IV clinical trials based on the framework that
integrates genomic, proteomic, physiological and environmental information in the context of the disease.
Specific patient scenarios can be generated and drug solutions trialled and the application of this system
at the basic research level as a tool for modelling disease progression warrants further exploration. Using
genomic- and proteomic-based technologies at this level, as well as in drug discovery, can provide useful
information; yet they often fail when trying to expand to the bigger picture (i.e. how these potential targets
are regulated or their wider role in disease states). This is where in silico technology, such as the
PhysioLab technology model, can add value, by using a top-down approach, relating clinical outcomes to
disease specificities and to human biology and physiology. In a hypothetical research strategy, following
creation of a virtual patient, hypotheses regarding gene function can be generated and tested through
simulation of the human response and subsequently validated through in vitro experimentation.
If the development of computational processing potential fol-lows Moore’s law of doubling every 18–24
months, in silico repre-sentations will be available to identify physical manifestations of disease very soon
[150]. To understand the complexity of biolo-gical processes, the in silico approach enables rapid
integration of new data and knowledge. It cannot be forgotten that computa-tional models do require
experimental validation and, therefore, might simply have a role in providing insights for further research.
Models can only be as accurate as the databases from which they are derived [135]. Additionally, the
complexity, at the biological level, of in silico models are less predictive at the organ and organism level
[74]. Regardless, it is no surprise that mathematical models are being heralded as a key to
comprehension of complex diseases; using a computational approach is paramount to unra-velling the
vast amounts of detailed data at an organ level [137].
Genetic studies
The concept of a universal ‘asthma gene’ is implausible, but there is no doubt that understanding the
genetics of asthma will lead to improvements in its diagnosis, prevention and treatment. Several
candidate genes with functional phenotypes involved in asthma have already been discovered [151], and
molecular phenotyping has an important role in the future of asthma research [58] and in directing basic
research trends.
Asthma is a complex inflammatory disorder whereby development is thought to be influenced by both
genetic and environ- mental factors. In asthma, the complexity of these interactions is such that the
genetic roots of this disease are difficult to uncover and interpret but represent the basis of why the
disease occurs in one person and not another. Linkage analysis makes use of poly-morphic markers
throughout the genome to determine affected patients in families [152], and analysis of inheritance
patterns in families and twins has enabled some genetic–pathogenic linkages to be identified in bronchial

asthma [153]. Numerous studies have examined candidate genes for associated disease and genetic
variation; a complex task when considering the number of asthma-associated traits available, such as
AHR, elevated IgE, atopy and airway remodelling. Genetic mapping studies have enabled genes of
interest to be identified [154], and linkage disequilibrium studies can identify polymorphisms with disease
associations. For example, the ADAM33 gene is thought to have a role in airway remodelling [155]. It is
common for genetic studies to progress into transgenic studies using animal models once candidate
genes are identified to investigate their contribution to pathophysiology. This must take into account the
complex interplay between environmental factors and genetic traits and the experimental contradictions
that can ensue [156]. Sidestep- ping the transgenic model in favour of a more human-relevant model
might see the significance of genetic factors appear more readily.
Epigenetic changes, such as DNA methylation, histone modifications, miRNA changes and chromatin
alterations after environmental exposures, are thought to be behind the variable incidence and remission
of symptoms in asthma. Therefore, scientists have suggested that the study of environmental epigenetics
holds immense promise in understanding a theoretically preventable disease [157]. Cohort-driven
epigenetic research has the potential to answer many genetic questions; longitudinal studies featuring
repeated measures of environmental exposures, collection of biological specimens over time and clinical
outcome assessments could add a wealth of information on specific environmental pressure points and
crucial windows of susceptibility. Used in conjunction with global screening methods, such as restriction
fingerprinting, restriction landmark genomic scanning, methylation of CpG island amplificationrepresentational difference analysis and methylation target microarrays, to identify candidate regions as
well as to reassess genes of interest, epigenomes susceptible to environmentally induced asthma could
be identified in the future [158]. Although there are many perplexing factors that will limit the ability to
study epigenetic pathways, there is still great promise in this field [157].
The integration of systems biology and bioinformatics is an exploratory approach to investigating asthma
genetics, according to which mathematical models are used to identify crucial asthma-related candidate
genes, the functions of which are then con-firmed by biological procedures and tested using biological
samples from different human populations and races. This strategy is an example of an integrated
approach, whereby research costs are reduced and research efficiency is increased. The
KEGGPATHWAY database (KEGG Pathway Database; http://www.genome.ad.jp/kegg/pathway.html) is
one such strategy consisting of many net-work maps of interactions between ligands and receptors in the
immunological system associated with asthma. This network map can be disassembled for analysis,
including the T-cell signalling pathway, where candidate genes are analysed and confirmed through highthroughput biological methods, such as resequencing and genotyping [159].
Use of the microarray technology platform combined with in vitro experimental approaches is another
approach to the identification of disease-associated genes. For example, human bronchial epithelial
cultures were probed for genes regulated by IL-4 and IL-13 and, through comparison with cDNA libraries,
several disease-associated genes have been identified. In combination with in vitro techniques [160], the
results were successfully corroborated [161]. There is a great need for bio-markers to become an integral
part of drug discovery and development. Microarray analysis provides a unique approach in profiling the
entire genome, offering insight into potential markers and thereby representing a vital tool for basic
research [162].
Exploiting available data: human models and/or patient studies
Clinical studies using volunteer patients [163] and their biological samples [160,164] are reasonably
common, but they could be better integrated into research strategies. The initiation of the Severe Asthma

Research Program (SARP) in the USA in 2000 was the first step toward recognising the need for
networking to address severe asthma characteristics. Patient data are shared across eight centres and,
since its establishment, SARP has pro-vided the numbers of subjects and depth of analysis required to
elucidate mechanisms underlying many phenotypes [165]. Through the engagement of asthmatic patient
volunteers, it has been possible to induce acute changes through controlled allergen challenge in a clinic,
an approach used for many years to study mechanisms of asthma in affected individuals [166]. A human
model of asthma exacerbation was also used to observe allergen inhalation challenge in patients with
asthma successfully to give insights into inflammatory mediator interplay and development of new drug
targets [167]. A less obvious use of patient data is in the wider use of electronic medical records for
clinical research, whereby investigators create a predictive model of chronic asthma using demographic
and co-morbidity data extracted from the ‘asthma data mart’ created by the US National Centre for
Biomedical Computing [168]. Bayesian networks were used to create a predictive and accurate model
with the potential to better under-stand disease trends in the future and inform basic medical research.
Concluding remarks
Unlike in regulatory testing, a common infrastructure for using 3Rs methods in basic research is rare.
Notwithstanding achievements made to date in the treatment of asthma, the relevance of artificial animal
models is considered to be overestimated in many cases, which could be contributing to the current
disease research climate (i.e. sufficient research but insufficient progress). With animal research, some
fundamental issues are often overlooked, such as species-dependent differences, limitations of
extrapolating data from animals to humans, lack of validation of animal methods, underreporting of pitfalls
and limitations of models and statistical under-powering of data. There is a lack of visibility of 3Rs
approaches and, until there is an appreciation of the value-added of these 21st-century tools and
technologies, such methods will not become an integral part of research. The benefits of expanding the
use of in vitro and computational approaches include lower cost, higher throughput, increased replicates,
simplicity, improved accessibility, reduction of variation and the use of human materials, all of which have
the strong potential to lead to more human-relevant research findings. Despite the ever-increasing
sophistication of in vitro and in silico tools and models, relatively few are being exploited to their full
potential in the basic research arena.
Laboratories often use different methods and protocols when researching common themes, making data
comparison difficult. It is also common for application of an alternative method to rarely extend beyond
the confines of the laboratory that invented it, without good reason. The models mentioned in this review
have their strengths and weaknesses, largely depending on the goal and application of research. Despite
the use of animal models and their ability to simulate some of the symptoms of asthma, the
disadvantages surrounding their use and the slow progress in this field brings to light the need to move
away from the historical paradigm and toward greater integration of 21st-century methodologies. Models
are an essential part of basic research; the use of 3D in vitro cell models of human airways not only
provides a powerful tool to deepen the knowledge already obtained on human asthma, but also
represents an ideal means for screening and identifying potential drug targets. There is also a wealth of
experimental data waiting to be used for method validation. The development of further tissueengineered, in vitro pulmonary equivalents is a promising way to reduce animal use in inhalation
research. It is undeniable that reliance on animal models might continue simultaneously as the field
begins to accept the benefits and robustness of non-animal approaches and as such methods develop,
but this strategised process of reduction will hopefully lead to replacement in many areas. There is also
an urgent need for further research integrating in vitro and in silico approaches, together with multidisciplinary programs, to foster cross-talk and synergies among scientific disciplines. A multidisciplinary
approach, integrating a broad range of techniques from 3D cell cultures to mathematical models and

using human patient data following a targeted and mapped out strategy, would not only reduce reliance
on animals, but would also create a more scientifically robust asthma research field with a potentially
more streamlined translation of research results from the bench to the clinic.
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